[
  {
    "patient_id": "1",
    "patient_data": {
      "ID": 1,
      "beschreibung": "G1-Case",
      "tumorboard_datum ": 12.2024,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.\n01/2017 V.a. neue Lebermetastase\n02/2017 Start Somatoline\n02/2018 CT Abdomen: stable disease\n03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. ",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen."
    },
    "matches_found": 1,
    "matches_with_publications": 1,
    "matches_with_posted_results": 1,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03365791",
        "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "1. **Diagnostic Match:** [Exact match] The study specifically includes a cohort for \"Advanced well-differentiated neuroendocrine tumors.\" The patient has a well-differentiated NET (G1) of the small intestine with metastatic disease, aligning perfectly with the cohort description. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient’s tumor is G1, and has metastasized to lymph nodes and the liver – fitting the “advanced” criteria within the study. While Ki-67 isn’t provided, ...",
        "has_posted_results": true,
        "condition": "Small Cell Lung Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Castration Resistant Prostate Adenocarcinoma; Soft Tissue Sarcoma; Ovarian Adenocarcinoma; Advanced Well-differentiated Neuroendocrine Tumors; Diffuse Large B Cell Lymphoma",
        "intervention": "PDR001; LAG525",
        "url": "https://clinicaltrials.gov/study/NCT03365791",
        "publications": {
          "nct_id": "NCT03365791",
          "study_title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
          "publications_found": 0,
          "publications": [],
          "status": "no_publications_found"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_1_clinical_trials_llm.txt"
  },
  {
    "patient_id": "2",
    "patient_data": {
      "ID": 2,
      "beschreibung": "G3-Case Initialdiagnose, Netter 2 analo",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie?",
      "Empfehlung": "PET- Bildgebung und PRRT planen, analog zur Netter 2 Studie."
    },
    "matches_found": 0,
    "matches_with_publications": 0,
    "matches_with_posted_results": 0,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_2_clinical_trials_llm.txt"
  },
  {
    "patient_id": "3",
    "patient_data": {
      "ID": 3,
      "beschreibung": "G2-Case, geringe SSTR Expression",
      "tumorboard_datum ": 8.2015,
      "main_diagnosis_text": "NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)\nKoloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.\n07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "FDG-PET und Everolimus Therapie starten."
    },
    "matches_found": 1,
    "matches_with_publications": 1,
    "matches_with_posted_results": 1,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT01524783",
        "title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
        "status": "COMPLETED",
        "phase": "PHASE3",
        "relevance_score": 1.0,
        "relevance_reason": "1. **Diagnostic Match:** [Exact match] The study specifically targets advanced Neuroendocrine Tumors (NET) of GI origin, which perfectly aligns with the patient’s diagnosis of a small bowel (Dünndarm) NET. The study inclusion criteria explicitly cover the patient’s primary tumor site. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient has a G2 NET with metastatic disease (lymph node and liver metastases). The study includes patients with advanced NETs, and doesn't exclude ...",
        "has_posted_results": true,
        "condition": "Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors",
        "intervention": "Everolimus; Placebo; Best suportive care (BSC)",
        "url": "https://clinicaltrials.gov/study/NCT01524783",
        "publications": {
          "nct_id": "NCT01524783",
          "study_title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)",
          "publications_found": 5,
          "publications": [
            {
              "pmid": "33560090",
              "title": "Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S...",
              "authors": [],
              "journal": "From Clinical Trial Data",
              "year": "N/A",
              "doi": null,
              "abstract": "Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb 1;50(2):130-137. doi: 10.1097/MPA.0000000000001745.",
              "url": "https://pubmed.ncbi.nlm.nih.gov/33560090/",
              "source": "study_data"
            },
            {
              "pmid": "29081664",
              "title": "Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle...",
              "authors": [],
              "journal": "From Clinical Trial Data",
              "year": "N/A",
              "doi": null,
              "abstract": "Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017.",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29081664/",
              "source": "study_data"
            },
            {
              "pmid": "29055056",
              "title": "Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Vo...",
              "authors": [],
              "journal": "From Clinical Trial Data",
              "year": "N/A",
              "doi": null,
              "abstract": "Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.",
              "url": "https://pubmed.ncbi.nlm.nih.gov/29055056/",
              "source": "study_data"
            },
            {
              "pmid": "28838862",
              "title": "Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek ...",
              "authors": [],
              "journal": "From Clinical Trial Data",
              "year": "N/A",
              "doi": null,
              "abstract": "Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30.",
              "url": "https://pubmed.ncbi.nlm.nih.gov/28838862/",
              "source": "study_data"
            },
            {
              "pmid": "26703889",
              "title": "Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pac...",
              "authors": [],
              "journal": "From Clinical Trial Data",
              "year": "N/A",
              "doi": null,
              "abstract": "Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.",
              "url": "https://pubmed.ncbi.nlm.nih.gov/26703889/",
              "source": "study_data"
            }
          ],
          "status": "success",
          "info_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\publications\\NCT01524783_publications.json"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_3_clinical_trials_llm.txt"
  },
  {
    "patient_id": "4",
    "patient_data": {
      "ID": 4,
      "beschreibung": "P-NET G2-Case, Compete Trial analog",
      "tumorboard_datum ": 8.2016,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n08/2015 Start Somatuline\n06/2016 DOTATOC PET: Progress der Lebermetastasen, starke Speicherung der Leberläsionen.",
      "Fragestellung": "Weitere Therapie, Everolimus oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 1,
    "matches_with_publications": 1,
    "matches_with_posted_results": 1,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [
      {
        "nct_id": "NCT03365791",
        "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "relevance_score": 1.0,
        "relevance_reason": "1. **Diagnostic Match:** [Exact match] The study specifically includes a cohort for \"Advanced well-differentiated neuroendocrine tumors.\" The patient has a pancreatic NET (NET des Pankreas) with metastatic disease, fitting this inclusion criterion. This is a precise match, not a broad \"NET\" category. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient has a G2 NET with lymph node and liver metastases. The study doesn't specify a grade restriction within the advanced NET coh...",
        "has_posted_results": true,
        "condition": "Small Cell Lung Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Castration Resistant Prostate Adenocarcinoma; Soft Tissue Sarcoma; Ovarian Adenocarcinoma; Advanced Well-differentiated Neuroendocrine Tumors; Diffuse Large B Cell Lymphoma",
        "intervention": "PDR001; LAG525",
        "url": "https://clinicaltrials.gov/study/NCT03365791",
        "publications": {
          "nct_id": "NCT03365791",
          "study_title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
          "publications_found": 0,
          "publications": [],
          "status": "no_publications_found"
        }
      }
    ],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_4_clinical_trials_llm.txt"
  },
  {
    "patient_id": "5",
    "patient_data": {
      "ID": 5,
      "beschreibung": "P-NET G2-Case Initial",
      "tumorboard_datum ": 6.2015,
      "main_diagnosis_text": "NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)\nCT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.\n07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.\n\n06/2015 DOTATOC PET: starke Speicherung der Läsionen.",
      "Fragestellung": "Weitere Therapie, Somatuline oder PRRT?",
      "Empfehlung": "PRRT starten."
    },
    "matches_found": 0,
    "matches_with_publications": 0,
    "matches_with_posted_results": 0,
    "llm_evaluation_method": "google/gemma-3-27b-it:free",
    "min_relevance_score": 1.0,
    "matches": [],
    "report_file": "C:\\Users\\pia\\OneDrive - Universitaet Bern\\Projects\\NetTubo\\netTubo\\clinical_trials_matches\\patient_5_clinical_trials_llm.txt"
  }
]